We are live on ! Find out more
EIDX

Eidos Therapeutics, Inc. Common Stock
EIDX

Delisted

EIDX was delisted on the 25th of January, 2021.

Back to rankings

78 hedge funds and large institutions have $418M invested in Eidos Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 26 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

567% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 3

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

25% more capital invested

Capital invested by funds: $334M → $418M (+$83.5M)

24% more funds holding

Funds holding: 63 → 78 (+15)

35% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 26

Holders
78
Holders Change
+15
Holders Change %
+23.81%
% of All Funds
1.69%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
20
Increased
17
Reduced
26
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$7.76M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.47M
3
PC
Polar Capital
United Kingdom
+$2.98M
4
OM
Opaleye Management
Massachusetts
+$2.86M
5
EU
Emory University
Georgia
+$2.27M

Top Sellers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
-$29.9M
2
BlackRock
BlackRock
New York
-$6.63M
3
SSA
Schonfeld Strategic Advisors
New York
-$3.18M
4
CS
Candriam SCA
Luxembourg
-$2.77M
5
FI
Fosun International
China
-$2.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$2.05M +$1.7M +62,541 +1,869%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$2.02M +$513K +18,933 +41%
Charles Schwab
28
Charles Schwab
California
$1.47M -$254K -9,361 -17%
Invesco
29
Invesco
Georgia
$1.44M +$37.5K +1,383 +3%
Allianz Asset Management
30
Allianz Asset Management
Germany
$1.31M -$95.6K -3,525 -8%
N
31
Nuveen
North Carolina
$1.29M +$1.12M +41,406 New
EGI
32
EAM Global Investors
California
$1.26M +$1.1M +40,688 New
PPA
33
Parametric Portfolio Associates
Washington
$1.09M +$950K +35,058 New
WC
34
Wexford Capital
Florida
$932K -$271K -10,000 -25%
ECM
35
ExodusPoint Capital Management
New York
$870K +$759K +27,992 New
Barclays
36
Barclays
United Kingdom
$855K -$178K -6,574 -19%
PP
37
Paloma Partners
Connecticut
$758K +$661K +24,399 New
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$737K +$374K +13,800 +139%
Millennium Management
39
Millennium Management
New York
$656K +$220K +8,133 +63%
AllianceBernstein
40
AllianceBernstein
Tennessee
$591K +$182K +6,700 +54%
Goldman Sachs
41
Goldman Sachs
New York
$580K -$28.8K -1,063 -5%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$530K -$221K -8,135 -32%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$520K -$60.6K -2,235 -12%
SEI Investments
44
SEI Investments
Pennsylvania
$454K +$396K +14,609 New
Swiss National Bank
45
Swiss National Bank
Switzerland
$426K +$371K +13,700 New
ProShare Advisors
46
ProShare Advisors
Maryland
$387K -$48.3K -1,782 -13%
SO
47
STRS Ohio
Ohio
$363K +$260K +9,600 +457%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$354K +$173K +6,400 +128%
Renaissance Technologies
49
Renaissance Technologies
New York
$333K +$290K +10,700 New
TEE
50
Tibra Equities Europe
United Kingdom
$333K +$290K +10,700 New
1
2
3 4

EIDX Hedge Fund Activity: Q2 2019 in Review

78 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q2 2019, worth a combined $418M — up 25% from $334M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new EIDX positions and 3 closed out — a net gain of 17 holders — while 17 added to existing stakes and 26 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $7.76M. The largest seller was Viking Global Investors, cutting an estimated $29.9M.

  • 78 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q2 2019, up from 63 in Q1 2019.
  • Funds reported $418M of Eidos Therapeutics, Inc. Common Stock stock for Q2 2019, up 25% quarter-over-quarter.
  • 20 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q2 2019 and 3 closed out, a net change of +17 holders.
  • The largest Eidos Therapeutics, Inc. Common Stock buyer in Q2 2019 was Lord, Abbett & Co, an estimated $7.76M added.
  • The largest Eidos Therapeutics, Inc. Common Stock seller in Q2 2019 was Viking Global Investors, an estimated $29.9M sold.

Based on aggregated 13F filings for Q2 2019.